Evidence map›Paper›PMID 37587466›Full record

ReviewHarm reduction journal2023

An answered call for aid? Cannabinoid clinical framework for the opioid epidemic.

Krista Hammaker, Nathaniel Weathington, Joseph Maroon, Lawton W Tang, Brian Donohue, Rachel Yehuda, Kenneth M Ford, Myro Figura, Ben Kelmendi, Belinda Tan and 7 more

Abstract readReview
In one paragraph

Review in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Krista HammakerNortheast Ohio Medical University, 4209 St Rt 44, PO Box 95, Rootstown, OH, 44272, USA.
Nathaniel WeathingtonThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Joseph MaroonThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Lawton W TangThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Brian DonohueThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Rachel YehudaThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Kenneth M FordThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Myro FiguraThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Ben KelmendiThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Belinda TanThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Matthew W CookThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Steven D FactorThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Laura LaganoThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Henry Patrick DriscollThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
Adam S HoweThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
EunBit G ChoThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA.
David M RabinThe Board of Medicine, 1942 5th Ave, Pittsburgh, PA, 15219, USA. drrabin@theboardofmedicine.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe opioid crisis continues in full force, as physicians and caregivers are desperate for resources to help patients with opioid use and chronic pain disorders find safer and more accessible non-opioid tools. MAIN BODY: The purpose of this article is to review the current state of the opioid epidemic; the shifting picture of cannabinoids; and the research, policy, and current events that make opioid risk reduction an urgent public health challenge. The provided table contains an evidence-based clinical framework for the utilization of cannabinoids to treat patients with chronic pain who are dependent on opioids, seeking alternatives to opioids, and tapering opioids.

conclusionBased on a comprehensive review of the literature and epidemiological evidence to date, cannabinoids stand to be one of the most interesting, safe, and accessible tools available to attenuate the devastation resulting from the misuse and abuse of opioid narcotics. Considering the urgency of the opioid epidemic and broadening of cannabinoid accessibility amidst absent prescribing guidelines, the authors recommend use of this clinical framework in the contexts of both clinical research continuity and patient care.

Indexed as

Chronic PainEpidemicsAnalgesics, OpioidHumansNarcoticsOpioid EpidemicAnalgesics, OpioidNarcoticsCannabinoidsChronic painOpioids

Identifiers

PMID37587466
PMCPMC10428550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.